Table 1.

Results of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Studies in Patients with Histologically Confirmed Non-small Cell Lung Cancer and Adrenal Lesions

Study	# NSCLC/patients (%)	Mean size in cm (range)	Histologic diagnosisa	Sensitivity	Specificity	Miscellaneous
Erasmus 19976	24/27 (89%)	3.0 (1.0–9.0)	11	100 %	80%	PET/CT accurate in 23/23 true-positives; 2 false+patients had FDG uptake of 3.0 and 3.7
Gupta 20017	27/30 (90%)	NR	7	94.4%	91.6%	PET/CT accurate in 17/18 true-positives, 11/12 true-negatives; 1 false-negative+adrenal schwannoma
Sung 20088	39/42 (87%)	1.6 (0.5–10.4)	9	80%	89%	PET/CT accurate in 28/35 true-positives and 23/26 true-negatives
Brady 20099	NR/76b	2.2±1.4c	12	97%	86%	92 excluded masses; PET/CT using strict SUVmax and ratio criteria accurate in 22/37 true-positives and 58/58 true-negatives
Okada 200910	23/30 (77%)	2.0±0.85c	0	89%	94%	PET/CT using strict SUVmax and ratio criteria accurate in accurate in 18/19 true-positives and 16/16 true-negatives
Lu 201011	NR/87	1.8 (0.4–5.8)	3	97%	94%	PET/CT accurate in 74/77 true-positives and 31/33 true-negatives
Cho 201112	43/51 (84%)	2.8 (1.0–7.2)	2	97%	81%	PET/CT accurate in 43/45 true-positives and 13/16 true-negatives using strict SUVmax and ratio criteria
Total	NC/343	2.2 (0.4–10.4)	44	94%	85%	Limitations: Many studies exclude indeterminate masses or questionable lesions with insufficient follow-up

^aNonhistologic adrenal mass determination made by CT change in nodule at ≥6 follow-up (malignancy=nodule growth; benign=stable or reduced nodule size).

^bSome patients had “suspected” lung cancer.

^cMean lesion size±standard deviation.

NSCLC=non-small cell lung cancer; PET/CT=positron-emission tomography/computed tomography; FDG=fluorine-18 fluorodeoxyglucose; NR=not reported; SUV=standard uptake value; NC=not calculable because of missing variables.